Advertisement

Search Results

Advertisement



Your search for all items matches 530 pages

Showing 351 - 400


leukemia
issues in oncology

Reduced Relapse but No Quality-of-Life Benefit With ATRA/Arsenic Trioxide vs ATRA/Idarubicin in Acute Promyelocytic Leukemia

In a UK-based phase III trial (AML17) reported in The Lancet Oncology, Burnett et al found that a chemotherapy-free regimen of arsenic trioxide plus all-trans retinoic acid (ATRA) did not improve quality of life, the primary endpoint, vs ATRA plus idarubicin in patients with acute promyelocytic...

leukemia

Inotuzumab Ozogamicin Receives FDA Breakthrough Therapy Designation for Acute Lymphoblastic Leukemia

Pfizer announced that the investigational antibody-drug conjugate inotuzumab ozogamicin received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for acute lymphoblastic leukemia (ALL). The Breakthrough Therapy designation was based on the results of the phase III...

leukemia

Dactinomycin Produces Durable Response in Patient With NPM1-Mutant AML

As reported by Falini et al in a letter to The New England Journal of Medicine, dactinomycin treatment resulted in morphologic and molecular complete remission ongoing at 14 months in a patient with NPM1-mutant acute myeloid leukemia (AML). NPM1-mutated AML may account for one-third of AML in...

leukemia
issues in oncology

Researchers Identify Dozens of Genetic Mutations Driving CLL and Their Evolution in Progression and Relapse

An analysis of whole-exome sequencing data from 538 patients with chronic lymphocytic leukemia (CLL), including 278 pretreatment samples collected from patients enrolled in a clinical trial, has identified 44 recurrently mutated genes and 11 recurrent somatic copy number variations. These findings...

hematologic malignancies
leukemia
lymphoma
issues in oncology

Half-Matched Bone Marrow Transplant Recipients May Tolerate Transplantation Just as Well as Fully Matched Recipients

Bone marrow transplantation is a lifesaving therapy for many patients with blood cancers like leukemias and lymphomas. Currently, the gold standard blood-generating stem cells are obtained from a donor, most likely a sibling, with a perfect match to the patient in order to minimize the chance of...

leukemia

Ofatumumab Maintenance Improves Progression-Free Survival in Responders to Second- or Third-Line CLL Treatment

In an interim analysis of the phase III PROLONG trial reported in The Lancet Oncology, van Oers et al found that maintenance therapy with ofatumumab (Arzerra) prolonged progression-free survival vs observation in patients with chronic lymphocytic leukemia in complete or partial remission after...

leukemia

Long-Term Remissions Reported in CLL Personalized Cell Therapy Trial

In the first trial of the University of Pennsylvania's personalized cellular therapy for chronic lymphocytic leukemia (CLL), 8 of 14 patients responded to the therapy, with some complete remissions continuing past 4.5 years. These results, published by Porter et al in Science Translational...

leukemia
lymphoma

Chemotherapy Pretreatment May Boost Effectiveness of CAR T-Cell Therapy in Patients With Lymphoma and Leukemia

A small phase I/IIa study of third-generation CD19 CAR (chimeric-antigen receptor) T-cell therapy combined with chemotherapy pretreatment has resulted in complete responses in 6 of the 11 patients with relapsed or refractory lymphoma and leukemia enrolled in the study. Although CAR T-cell...

leukemia
myelodysplastic syndromes
issues in oncology

Study Explores Link Between Allele Expression and Risk of Graft-vs-Host Disease in Transplant Recipients

In a study reported in The New England Journal of Medicine, Petersdorf et al found a greater risk of acute graft-vs-host disease among hematopoietic cell transplant recipients with the high-expression rs9277534G allele linked to mismatched HLA-DPB1 who received transplants from donors with the...

leukemia
issues in oncology

Persistent Leukemia-Associated Mutations After Induction Therapy Predict Poorer Outcome in AML

In a study reported in JAMA, Klco et al found that persistence of leukemia-associated mutations in ≥ 5% of bone marrow cells at remission predicted poorer outcome among patients with acute myeloid leukemia (AML), including those with intermediate-risk disease. Study Details In the study,...

leukemia

BRAF Inhibition Successful in Relapsed/Refractory BRAF V600E–Mutant Hairy Cell Leukemia

In two phase II studies reported in The New England Journal of Medicine, Tiacci et al found that the BRAF inhibitor vemurafenib (Zelboraf) produced responses in nearly all patients with BRAF V600E–positive hairy cell leukemia who relapsed after treatment with a purine analog or who had...

leukemia

No Difference in Overall Survival With Addition of Quinolone Derivative Vosaroxin to Cytarabine in Relapsed or Refractory AML

In a phase III VALOR trial reported in The Lancet Oncology, Ravandi et al found that the addition of the quinolone derivative vosaroxin to cytarabine did not significantly improve overall survival in patients with relapsed or refractory acute myeloid leukemia (AML). However, differences favoring...

leukemia
issues in oncology

Leukemia Renewal and Propagation Blocked by Inhibition of Surface Molecule

A new study by researchers at the University of California, San Diego, School of Medicine, reveals a protein’s critical—and previously unknown—role in the development and progression of acute myeloid leukemia (AML). The finding offers a novel target for better treating AML, and...

cns cancers
gynecologic cancers
colorectal cancer
leukemia
lymphoma
skin cancer
gynecologic cancers
issues in oncology
issues in oncology
issues in oncology

Noninvasive Prenatal Testing May Also Detect Some Maternal Cancers

A study published by Bianchi et al in the Journal of the American Medical Association (JAMA) showed that genetic test results revealed by noninvasive prenatal testing for fetal chromosomal abnormalities may detect underlying conditions in the mother, including cancer. The study reports on a case...

leukemia

Preclinical Studies Demonstrate Activity of Type II JAK2 Inhibitor in B-Cell ALL

Laboratory and animal tests of the type II inhibitor CHZ868, which stabilizes the kinase domain in an inactive conformation, are showing that the compound is highly potent against B-cell acute lymphoblastic leukemias (ALLs) with CRLF2 rearrangements. When combined with dexamethasone, CHZ868 induced ...

health-care policy
hematologic malignancies
leukemia
issues in oncology
issues in oncology
cost of care

Study Finds Current Prices of Hematologic Cancer Drugs Are Not Justified

The costs associated with cancer drug prices have risen dramatically over the past 15 years, a trend concerning to many oncologists. In a new analysis, researchers at The University of Texas MD Anderson Cancer Center concluded that the majority of existing treatments for hematologic cancers are...

leukemia
issues in oncology

ETV6 Mutation May Trigger Lymphoblastic Leukemia

The results of a nearly 10-year investigation that identified a key gene mutation that can trigger acute lymphoblastic leukemia (ALL) and several other types of cancer were recently published by Noetzli et al in Nature Genetics. The findings have, for the first time, pinpointed a mutation that...

hematologic malignancies
leukemia
issues in oncology

Importance of Establishing Definitions to Increase Survival After Blood/Marrow Transplant

Blood and marrow transplantation is a potentially curative treatment for patients with leukemia or other life-threating blood diseases. With a goal of increasing survival rates, a research team led by Roswell Park Cancer Institute (RPCI) investigators verified patient outcome data submitted by more ...

leukemia
lymphoma
survivorship

Long-Term Follow-Up Suggests No Detrimental Survival Effect of Dexrazoxane in Pediatric Patients With Leukemia or Lymphoma

In an analysis of Children’s Oncology Group (COG) trials reported in the Journal of Clinical Oncology, Chow et al found that dexrazoxane use did not appear to be associated with poorer survival among pediatric patients with leukemia or lymphoma in long-term follow-up. Study Details The...

leukemia
issues in oncology

DNMT3A Mutations Predict Poorer Outcome in Younger Adults With AML Irrespective of NPM1 Genotype, but Type of Mutation Matters

In a UK study reported in the Journal of Clinical Oncology, Gale et al found that presence of DNMT3A mutations was associated with poorer prognosis in young adults with cytogenetic intermediate-risk acute myeloid leukemia (AML) irrespective of the presence of NPM1 mutation. Poorer outcome was found ...

leukemia
lymphoma
survivorship

ASCO 2015: Reduction in Late Mortality Among Childhood Cancer Survivors Linked to Improvements in Cancer Care

Survivors of childhood cancer in recent eras have shown a significant reduction in late mortality, and “for the first time, we have been able to attribute that to fewer deaths from treatment-related causes or fewer deaths from late effects of the primary therapy,” Gregory T....

leukemia

ASCO 2015: New Ibrutinib Combination Regimen Shows Substantial Benefits in Relapsed Chronic Lymphocytic Leukemia

First results from a randomized phase III study show that the combination of ibrutinib (Imbruvica) and bendamustine (Treanda)/rituximab (Rituxan) improves outcomes for patients with chronic lymphocytic leukemia (CLL) that progressed despite prior therapy. At a median follow-up of 17 months,...

hematologic malignancies
leukemia
multiple myeloma
lymphoma

Study Links Paternal Age to Child’s Risk of Developing Blood and Immune System Cancer in Adulthood

A new study links a father's age at birth to the risk that his child will develop blood and immune system cancers as an adult, particularly for only children. The study, published by Teras et al in the American Journal of Epidemiology, found no association between having an older mother and these...

leukemia

FDA Fast Track Designation Granted to AG-120 for Treatment of Patients With IDH1-Mutated Acute Myeloid Leukemia

The U.S. Food and Drug Administration had granted Fast Track designation to AG-120 for the treatment of patients with acute myeloid leukemia who harbor an isocitrate dehydrogenase-1 (IDH1) mutation. Agios Pharmaceuticals’ AG-120 is a first-in-class, oral, selective, potent inhibitor of the...

leukemia

Venetoclax Receives Breakthrough Therapy Designation in Relapsed/Refractory CLL With 17p Deletion

The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to AbbVie’s investigational agent venetoclax (ABT-199) for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) in patients with the 17p deletion. Venetoclax is an investigational oral...

leukemia

Subgroup of Elderly Patients With Acute Myeloid Leukemia May Benefit From Initial Intensive Induction Chemotherapy

Initial intensive induction chemotherapy may be of benefit in a subgroup of newly diagnosed elderly patients with acute myeloid leukemia (AML), according to a study by Ross et al in Oncology Research. However, relapse rates remained high. Elderly patients with AML generally experience worse...

leukemia

Addition of Ofatumumab to Chlorambucil Increases Progression-Free Survival in Previously Untreated CLL Patients Who Are Not Candidates for Fludarabine

In the phase III COMPLEMENT 1 trial reported in The Lancet, Hillmen et al found that the addition of the anti-CD20 antibody ofatumumab (Arzerra) to chlorambucil (Leukeran) increased progression-free survival among patients with chronic lymphocytic leukemia (CLL) who were not considered candidates...

leukemia

Single-Center Experience Indicates Relatively Good Prognosis After Allogeneic Stem Cell Transplantation Failure in CLL

In a retrospective single-center study reported in Journal of Clinical Oncology, Rozovski and colleagues found that chronic lymphocytic leukemia (CLL) patients with disease progression after allogeneic stem cell transplantation had a relatively good prognosis, with apparent benefit of salvage...

hematologic malignancies
leukemia

AACR 2015: New T Cell–Based Immunotherapy Shows Promise for Lethal Stem Cell Transplant Complication

More than 60% of patients with Epstein-Barr virus–associated lymphoproliferative disorder (EBV-LPD) that was nonresponsive to standard rituximab (Rituxan) treatment responded to a new type of immunotherapy called Epstein-Barr virus–specific cytotoxic T-lymphocyte (EBV-CTL) therapy....

leukemia

Less Than 95% Adherence to Mercaptopurine Maintenance Associated With Nearly Threefold Increased Risk of Relapse in Pediatric ALL

In a Children’s Oncology Group study (COG-AALL03N1) reported in JAMA Oncology, Bhatia et al found that < 95% adherence to mercaptopurine treatment was associated with a nearly threefold increase in the risk of relapse in children with acute lymphoblastic leukemia (ALL). Among adherent...

leukemia

Patients With Relapsed or Refractory CLL Who Discontinue Ibrutinib Early Have Poor Outcomes

Most patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who discontinued ibrutinib (Imbruvica) early “were difficult to treat and had poor outcomes,” according to a study of patients enrolled in four different clinical trials of ibrutinib, with or without rituximab...

leukemia

No Improvement in Complete Remission Rate With Cytarabine Plus Amonafide L-Malate vs Daunorubicin in Secondary AML

In a phase III trial reported in the Journal of Clinical Oncology, Stone et al found that the combination of cytarabine and amonafide L-malate, a DNA intercalator and non–ATP-dependent topoisomerase II inhibitor, did not improve complete remission rate compared with cytarabine plus...

leukemia

No Difference in Event-Free Survival With Stem Cell Transplantation Using Matched Unrelated vs Sibling Donor Grafts in Children With ALL

In a European trial (Berlin-Frankfurt-Muenster study group trial ALL-SCT-BFM 2003) reported in the Journal of Clinical Oncology, Peters et al found no difference in event-free survival with stem cell transplantation using matched unrelated vs sibling donors in pediatric patients with high-risk...

leukemia

Measuring Minimal Residual Disease Levels Proves to Be a Powerful Tool for Guiding Leukemia Treatment

According to a prospective study led by researchers at St. Jude Children's Research Hospital, measuring the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy may help boost survival of young leukemia patients by better matching patients with the right...

leukemia
issues in oncology

Chromosomal Rearrangement May Be the Key to Progress Against Aggressive Infant Leukemia

The St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project reports that a highly aggressive form of leukemia in infants has surprisingly few mutations beyond the chromosomal rearrangement that affects the MLL gene. The findings, reported by Andersson et al ...

leukemia

Factors in Ibrutinib Discontinuation in Patients With Chronic Lymphocytic Leukemia

In a single-center study reported in JAMA Oncology, Maddocks et al found that Richter’s transformation accounted for early progression-related discontinuation of ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) and that CLL progression but not Richter’s...

leukemia

Durable Responses at 3-Year Follow-up for CLL Patients Receiving Single-Agent Ibrutinib

At a median follow-up of 3 years, ibrutinib (Imbruvica) demonstrated continued activity with durable responses that improved in quality with extended treatment of patients with chronic lymphocytic leukemia (CLL). In addition, grade 3 toxicity and adverse events leading to discontinuation diminished ...

leukemia
supportive care
issues in oncology

Inherited Gene Variation Leaves Young Leukemia Patients at Risk for Peripheral Neuropathy

St. Jude Children’s Research Hospital scientists have identified the first genetic variation that is associated with an increased risk and severity of peripheral neuropathy following treatment with a widely used anticancer drug. Investigators also found evidence of how it may be possible to...

leukemia
lymphoma
issues in oncology

Study Shows Immunosuppressives, Chemotherapy May Reactivate Hepatitis B

Individuals previously infected with the hepatitis B virus (HBV) that receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the virus, according to a report published by Di Bisceglie et al in Hepatology. Reactivation of HBV can be fatal, and researchers suggest routine...

leukemia

Ibrutinib Active in Previously Untreated and Relapsed/Refractory CLL With TP53 Aberrations

In a phase II study reported in The Lancet Oncology, Farooqui et al found that single-agent ibrutinib (Imbruvica) had good activity in patients with previously untreated or relapse/refractory chronic lymphocytic leukemia (CLL) with TP53 aberrations. Study Details In this single-arm trial, 51...

leukemia
issues in oncology

Inherited Gene Variation Helps Explain Drug Toxicity in ALL Patients of East Asian Ancestry

Scientists at St. Jude Children's Research Hospital have discovered about 10% of young leukemia patients of East Asian ancestry inherit a gene variation that is associated with reduced tolerance of a drug that is indispensable for curing acute lymphoblastic leukemia (ALL), the most common childhood ...

leukemia
issues in oncology

Protein-Based Therapy Shows Promise Against Resistant ALL in Preclinical Study

Chemotherapy resistance is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Now researchers at Children’s Hospital Los Angeles (CHLA) have designed and developed a new protein-based therapy that may prove highly...

leukemia
issues in oncology

TP53 Mutations May Play a Role in Treatment‑Related Acute Myeloid Leukemia and Myelodysplastic Syndrome

A genomic study of cancer patients previously treated with chemotherapy or radiation therapy found that TP53 mutations may play a role in the development of treatment-related acute myeloid leukemia (AML) and myelodysplastic syndrome, according to a report by Wong et al in Nature. However, the...

leukemia

CPX-351 Receives Fast Track Designation for Secondary Acute Myeloid Leukemia in Elderly Patients

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Celator Pharmaceuticals’ investigational agent CPX-351, a liposomal formulation of cytarabine-daunorubicin, for the treatment of elderly patients with secondary acute myeloid leukemia. The FDA established the...

leukemia
issues in oncology

Allogeneic Stem Cell Transplantation Prolongs Recurrence-Free Survival in NPM1-Mutant AML

In an analysis of the Study Alliance Leukemia (SAL) AML 2003 trial reported in the Journal of Clinical Oncology, Röllig et al found that allogeneic stem cell transplantation significantly prolonged recurrence-free survival in patients with NPM1-mutant acute myeloid leukemia (AML). NPM1...

leukemia

Bispecific CD19-Directed CD3 T-Cell Engager Blinatumomab Active in Adults With Relapsed/Refractory B-Cell Precursor ALL

In a phase II study reported in The Lancet Oncology, Topp et al found that the bispecific CD19-directed CD3 T-cell engager (BiTE) blinatumomab (Blincyto) was highly active in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab binds to CD19 expressed ...

leukemia

Long Noncoding RNAs Are a Novel Prognostic Marker in Older Patients With Acute Leukemia

A new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) describes a novel marker that might help doctors choose the least toxic, most effective treatment for many...

leukemia

ASH 2014: Pracinostat Combination Shows Significant Clinical Activity in Phase II Study of Newly Diagnosed Acute Myeloid Leukemia

In a phase II study, the histone deacetylase inhibitor pracinostat demonstrated significant clinical activity in combination with azacitadine in elderly patients with newly diagnosed acute myeloid leukemia (AML). Interim data from 33 evaluable patients were presented at the 56th American Society of ...

leukemia

ASH 2014: Oral Inhibitor Shows Clinical Activity in Poor-Prognosis AML

An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML), a poor-prognosis group with few options, reported investigators from Dana-Farber Cancer Institute and The University of Texas MD...

leukemia
survivorship

ASH 2014: Common Genetic Variations May Contribute to Treatment-Related Cognitive Problems in Children With Leukemia

Common variations in four genes related to brain inflammation or cells′ response to damage from oxidation may contribute to the problems with memory, learning, and other cognitive functions seen in children treated for acute lymphoblastic leukemia (ALL), according to a study presented at the...

Advertisement

Advertisement



Advertisement